Salix, Lupin deal
Salix granted Lupin exclusive rights to market Zaxine rifaximin 550 mg and subcutaneous Relistor methylnaltrexone in Canada. In Canada, Zaxine is approved to reduce the risk of overt hepatic encephalopathy (HE) recurrence in adult patients and subcutaneous Relistor is approved to treat opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. The deal also covers future dosage forms and indications for the products. Salix will receive an upfront payment and is eligible for milestones. Lupin has an option to license exclusive rights to market other gastroenterology products in Salix's Canadian pipeline once approved by Health Canada. The partners could not be reached for details. ...